Q-omics provides the consensus-scored PCDHGC3 profile across patient tissues and cancer cell-line models. PCDHGC3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHGC3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PCDHGC3 RNA expression shows 19,673 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where PCDHGC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGC3 survival associations across molecular data types. PCDHGC3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGC3 RNA expression–survival associations across cancer types. High PCDHGC3 expression shows unfavorable associations in BLCA, UVM and CESC, but favorable associations in KIRC, UCS and MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHGC3 RNA expression.
This table summarizes PCDHGC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDHGC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGC3 shows lower tumor expression in LUAD, KICH, BLCA and BRCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher PCDHGC3 RNA expression in tumor versus normal tissue (log2 FC = +1.586, t-test p < 0.001).
This table shows molecular features associated with PCDHGC3 in patient tissues and cancer cell lines. In patient samples, PCDHGC3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
